Zydus receives final approval from the USFDA for Aripiprazole Tablets

Published On: January 9th 2019 at 2:44 AM

cadila healthcare limitedZydus Cadila has received the final approval from the USFDA to market Aripiprazole Tablets USP (US RLD Abilify) in the strengths of2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Aripiprazole is an antipsychotic drug (atypical type). It is used to treat mental/mood disorders such as bipolar disorder, schizophrenia, Tourette’s disorder, and irritability associated with autistic disorder. It is also used in combination with other medications to treat depression. It works by helping to restore the balance of certain natural chemicals in the brain (neurotransmitters).

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

avatar
  Subscribe  
Notify of